Plain Language Summaries

Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience

Brain and nerves

A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets

This plain language summary from Neurodegenerative Disease Management describes the MAGNIFY-MS study, which investigated whether cladribine tablets affect how well the body responds to flu and chickenpox virus vaccines in people with multiple sclerosis.

Read the full article here.

The original article on which this plain language summary is based is titled ‘Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis’ and was published in the Multiple Sclerosis Journal. Read the original article here.

Plain language summary: what symptoms should be measured in clinical studies for early-stage Parkinson’s?

This plain language summary from Future Neurology describes the results of a study into which symptoms are most important to people with Parkinson’s in the earlier stages of their condition, and which symptoms would be appropriate to measure in future clinical studies.

Read the full article here.

The original article on which this plain language summary is based is titled ‘Patient Experience in Early-Stage Parkinson’s Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment’ and was published in Neurology and Therapy. Read the original article here.

Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary

The latest plain language summary of publication from Neurodegenerative Disease Management describes the findings from an international committee of 10 MS experts who developed recommendations to answer questions about COVID-19 vaccines in people with MS taking cladribine tablets.

Read the full article here.

The original article on which this summary is based is called ‘Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice’ and was originally published in the journal Therapeutic Advances in Neurological Disorders. The original article can be read here.

Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary

In this plain language summary of publication from Neurodegenerative Disease Management, Dr Gavin Giovannoni and co-authors provide an overview of their article originally published in the journal Advances in Therapy. In this article, the researchers look at the results from the CLARITY and CLARITY Extension studies to determine what effect a 2-year course of treatment with cladribine tablets had on disability over 5 years in people with multiple sclerosis.

Read the full article here.

The original article on which this summary is based is called ‘Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies’ and was originally published in the journal Advances in Therapy. The original article can be read here.

Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary

The latest plain language summary of publication from Neurodegenerative Disease Management presents the results from the CLARITY and CLARITY Extension studies, which looked at how well cladribine tablets work in treating people with multiple sclerosis.

Read the full article here.

The original article on which this summary is based is called ‘Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies’ and was originally published in the Multiple Sclerosis Journal. The original article can be read here.